Therapy response and outcome explained by leukemia cell of origin

Zhimin Gu; Kathryn E. Dickerson; Jian Xu

doi:10.1158/2159-8290.CD-20-1080

Therapy response and outcome explained by leukemia cell of origin

Zhimin Gu, Kathryn E. Dickerson, Jian Xu

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In this issue of Cancer Discovery, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor EVI1, apoptotic priming, and therapeutic susceptibility in mixed lineage leukemia– rearranged acute myeloid leukemia. These findings establish a cell of origin–dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.

Original language	English (US)
Pages (from-to)	1445-1447
Number of pages	3
Journal	Cancer discovery
Volume	10
Issue number	10
DOIs	https://doi.org/10.1158/2159-8290.CD-20-1080
State	Published - Oct 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-20-1080

Cite this

@article{a7ac66b00a8d4a38b3da28497c502ace,

title = "Therapy response and outcome explained by leukemia cell of origin",

abstract = "In this issue of Cancer Discovery, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor EVI1, apoptotic priming, and therapeutic susceptibility in mixed lineage leukemia– rearranged acute myeloid leukemia. These findings establish a cell of origin–dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.",

author = "Zhimin Gu and Dickerson, {Kathryn E.} and Jian Xu",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

month = oct,

doi = "10.1158/2159-8290.CD-20-1080",

language = "English (US)",

volume = "10",

pages = "1445--1447",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - Therapy response and outcome explained by leukemia cell of origin

AU - Gu, Zhimin

AU - Dickerson, Kathryn E.

AU - Xu, Jian

PY - 2020/10

Y1 - 2020/10

N2 - In this issue of Cancer Discovery, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor EVI1, apoptotic priming, and therapeutic susceptibility in mixed lineage leukemia– rearranged acute myeloid leukemia. These findings establish a cell of origin–dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.

AB - In this issue of Cancer Discovery, Cai and colleagues delineate a new mechanism that links cell of origin, the transcription factor EVI1, apoptotic priming, and therapeutic susceptibility in mixed lineage leukemia– rearranged acute myeloid leukemia. These findings establish a cell of origin–dependent program that may be leveraged by therapeutic combinations to overcome drug resistance in chemoresistant leukemias.

UR - http://www.scopus.com/inward/record.url?scp=85100209311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100209311&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-20-1080

DO - 10.1158/2159-8290.CD-20-1080

M3 - Article

C2 - 33004477

AN - SCOPUS:85100209311

SN - 2159-8274

VL - 10

SP - 1445

EP - 1447

JO - Cancer discovery

JF - Cancer discovery

IS - 10

ER -

Therapy response and outcome explained by leukemia cell of origin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this